On Monday, the Russian Direct Investment Fund (RDIF) and the pharmaceutical business Panacea Biotec announced that production of the Sputnik V vaccine against Coronavirus will begin in India this summer.
On April 12, India filed Sputnik V under the emergency use authorization process, and on May 14, coronavirus vaccinations using the Russian vaccine began. In April, RDIF and Panacea announced their partnership to manufacture 100 million doses of Sputnik V annually.
Panacea Biotec’s Baddi facilities will be sending their first batch to the Gamaleya Centre in Russia for quality assurance testing. This summer is when mass manufacture of the vaccine will begin. According to RDIF’s official statement, “Company’s facilities comply with GMP [good manufacturing practise] standards and are prequalified by WHO.”
The launch of manufacturing in India in collaboration with Panacea Biotec is a significant milestone in our efforts to aid the Indian government in its battle against the pandemic. Kirill Dmitriev, CEO of the Russian Direct Investment Fund, made the announcement. “Production of Sputnik V supports efforts of India’s authorities to leave behind the acute phase of coronavirus as soon as possible, while the vaccines will also be exported at a later stage to help prevent the spread of the virus in other countries around the world,” he said.
This is a major milestone as we start making Sputnik V. We at Panacea Biotec are committed to working with RDIF to restore a feeling of normality in the lives of individuals all around the globe. In contrast to vaccinations that utilise the same delivery mechanism for both doses, Sputnik V employs two separate vectors for the two shots in a course of vaccination, producing protection that lasts far longer.
It was created by the Gamaleya National Centre in Russia. It will join Covaxin and Covishield as the third vaccine approved for use in India’s national vaccination plan. In response to a worrisome increase in new Covid-19 infections in India, the Drugs Controller General of India (DCGI) issued a limited use authorization for Sputnik V last month. According to reports, Sputnik V is the world’s first vaccination against Covid-19, with an effectiveness of 91.6%.
Russia green-lit the Sputnik V on August 11 of last year. The vaccine has been given the go light for widespread distribution in over 50 nations, according to a study in the Lancet Medical Journal. The RDIF has agreed to manufacture 750,000,000 doses of Sputnik V in India. Sputnik V may be purchased across the globe at a cost of less than $10 each round. On May 1, 150,000 pills were sent to Hyderabad, and on May 16, another 60,000 doses were sent.
